Dr Reddy’s Laboratories Q4 FY2026 Results: Net Profit Crashes 86% — What Investors Must Know
By Kaushik Brahmakshatriya
Published On 13 May 2026.
Dr Reddy’s Q4 FY2026 Results
Dr Reddy’s Laboratories Ltd (NSE: DRREDDY) announced its fourth quarter results for FY2026 on May 12, 2026, and the numbers delivered a sharp reality check to investors. The Hyderabad-based pharmaceutical giant posted an 86% year-on-year collapse in net profit — a steep fall driven almost entirely by the loss of limited exclusivity on its blockbuster oncology drug, Lenalidomide (generic version of Revlimid).
While the headline numbers look alarming, the story beneath the surface is more nuanced. The company’s base business continued to perform well, India revenues posted double-digit growth, and the management remains optimistic about margins bouncing back in FY2027. Let’s break down everything you need to know.
Q4 FY2026: Key Financial Highlights at a Glance
Dr Reddy’s Q4 FY2026 vs Q4 FY2025 — Profit & Loss Summary
| Financial Metric | Q4 FY2026 | Q4 FY2025 | Year-on-Year Change |
| Revenue from Operations | ₹7,516 crore | ₹8,506 crore | ▼ 11.6% |
| Adjusted Revenue (ex-SSA) | ₹7,970 crore | ₹8,506 crore | ▼ 6.3% |
| Gross Margin | 44.8% | ~55.9% | ▼ ~1,074 bps |
| EBITDA | ₹981 crore | ₹1,998 crore | ▼ 60% |
| EBITDA Margin | 13% | 29.1% | ▼ 1,610 bps |
| Net Profit (PAT) | ₹221 crore | ₹1,587 crore | ▼ 86% |
| Impairment Charges | ₹258.6 crore | ₹27.1 crore | — |
Why Did Profit Collapse 86%? The Lenalidomide Effect Explained
The root cause of this dramatic earnings decline is straightforward: Dr Reddy’s limited exclusivity for Lenalidomide expired on January 31, 2026. Until that date, the company had enjoyed restricted competition and premium pricing for its generic version of the cancer drug. Once the exclusivity ended, multiple generic manufacturers entered the market, leading to severe price erosion.This single product accounted for a massive share of North America revenues. In Q4 FY2026, revenue from North America generics fell 51% year-on-year to ₹1,756 crore — down sharply from ₹3,559 crore in Q4 FY2025.
Beyond Lenalidomide, the quarter was further weighed down by:
* A Shelf Stock Adjustment (SSA) of ₹453 crore — a one-time inventory write-down related to Lenalidomide pricing corrections in the supply chain
* Impairment charges of ₹258.6 crore — including the discontinuation of CAR-T therapy R&D programs and write-off of partnered asset Eftilagimod Alpha
* Additional provisioning from India’s new Labour Code booked in Q3 FY2026 that continued to affect margins
Segment Performance: Where Did the Company Stand?
Geography-Wise Revenue Performance — Q4 FY2026
| Geography | Q4 FY2026 RevenueChange | Q4 FY2025 Revenue | Change |
| North America (Generics) | ₹1,756 crore | ₹3,559 crore | ▼ 51% |
| India (Generics) | ₹1,566 crore | ₹1,305 crore | ▲ 20% |
| Europe & Rest of World | Growth reported | Growth reported | Double-digit ▲ |
| Branded Markets (Russia, etc.) | Supported by currency tailwinds | — | Positive |
India’s performance stood out as a bright spot. Domestic generics revenues grew 20% year-on-year to ₹1,566 crore, demonstrating that the company’s India business is gaining strength. Europe and other international markets also delivered double-digit growth, partially cushioning the North America blow.
FY2026 Full Year: Modest Annual Growth Despite Q4 Pain
Despite the dismal Q4, the full-year picture for FY2026 holds up relatively better:
* Full-year revenue from operations: ₹33,593 crore — up 3% from ₹32,553 crore in FY2025
* Adjusted annual revenue (ex-SSA): ₹34,050 crore — representing a 4.6% year-on-year growth
* Full-year gross margin: 52.8%, down 573 basis points from FY2025 primarily due to Lenalidomide erosion
* Full-year PAT: ₹42,850 million (attributable to equity holders)
* The company achieved its highest-ever annual revenues for FY2026 on an overall consolidated basis
Growth was broad-based across geographies, with North America being the sole exception. Currency tailwinds from a weaker rupee against the dollar also provided partial support to overall revenues.
Dividend Declared: ₹8 Per Share (800% Payout)
Despite the weak Q4, Dr Reddy’s board rewarded shareholders with a generous dividend. The final dividend of ₹8 per equity share has been recommended, which translates to 800% of the face value of ₹1 per share.
Key dates to note:
* Record Date: July 10, 2026 (to determine eligible shareholders)
* Annual General Meeting: July 23, 2026 (where dividend will be formally approved
New Product Launches & Pipeline Progress
Dr Reddy’s didn’t just defend — it also made meaningful strategic progress during Q4 FY2026:
* Generic Semaglutide Injection launched in India — a significant step in the company’s peptide science strategy, targeting the fast-growing diabetes and obesity segment
* First-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution in the US — a competitive win in the eye care space
* Received regulatory approval for Semaglutide Injection in Canada (first company to do so), marking a key milestone in its international peptide commercialization
* Launched 10 new brands during Q4, taking total FY2026 new brand launches to 28
* Integration of 95% of the acquired consumer healthcare business completed successfully
Management Commentary & FY2027 Outlook
Dr Reddy’s FY2027 Key Targets vs FY2026 Actuals
| Parameter | FY2026 Actual | FY2027 Target / Guidance |
| Adjusted EBITDA Margin | ~19.5–20% | Aspirational 25%+ |
| Gross Margin | 52.8% (full year) | Above 50% |
| Base Business Growth | Double-digit | Continued double-digit |
| North America Recovery | Weak (Lenalidomide impact) | New launches + product mix |
| Semaglutide (India & Canada) | Launch phase | Scale-up planned |
Co-Chairman and Managing Director G V Prasad acknowledged the challenges while striking an optimistic tone: the resilience of branded businesses and currency tailwinds helped partially mitigate the Lenalidomide shock. The management has outlined a clear roadmap — new product launches, pipeline commercialization (especially semaglutide and abatacept), and continued cost optimization — to push EBITDA margins toward the aspirational 25% target.
The company’s adjusted EBITDA for Q4 FY2026, including other income, stood at ₹1,554 crore — a margin of 19.5% on adjusted revenues, showing that underlying business health is more solid than the reported headline numbers suggest.
Stock Market Reaction
On the day of the results (May 12, 2026), Dr Reddy’s shares closed at ₹1,270 on NSE, a decline of 0.77%. In US premarket trading (for the ADR), the stock fell further by 5.52% to $12.65, reflecting investor concern over the revenue miss versus analyst estimates of $893 million against the actual adjusted revenue of $849 million.
Q&A: Investor Questions Answered
Q1. Is Dr Reddy’s 86% profit fall a sign of structural weakness or a one-time event?
It is primarily a one-time structural shift. The expiry of Lenalidomide’s limited exclusivity on January 31, 2026, was a known event. With multiple generics now allowed in the US market, pricing has normalized. This will not reverse, but the company does not expect another product-specific cliff of this magnitude in the near term.
Q2. Should investors be worried about the ₹453 crore Shelf Stock Adjustment?
The SSA is a one-time non-recurring accounting charge. It reflects inventory adjustments in the supply chain triggered by Lenalidomide’s sharp price decline. This charge will not repeat in FY2027, which is why adjusted margins look much healthier (19.5%) versus reported EBITDA margins (13%).
Q3. Is Semaglutide the next big growth driver for Dr Reddy’s?
Potentially, yes. Dr Reddy’s has become the first company globally to receive regulatory approval for Semaglutide injection in Canada. With an India launch already done and scale-up underway, Semaglutide (used for Type 2 diabetes and increasingly for weight management) is one of the company’s highest-priority pipeline assets alongside Abatacept (a biosimilar).
Q4. Is the ₹8 dividend good news given weak quarterly profits?
Yes — it signals management’s confidence in the long-term cash generation ability of the business. An 800% dividend despite an 86% profit drop in Q4 reflects that the cash flows at the operational level remain intact and that the profit decline was largely accounting/one-off in nature.
Q5. What is the FY2027 outlook for Dr Reddy’s stock?
Management has guided for gross margins above 50%, adjusted EBITDA margins pushing toward 25%, and double-digit base business growth. Analysts have mixed views
— Bank of America maintains a Buy with a target of ₹1,540, while Citi has a Sell rating with a ₹1,070 target. Investors should monitor new US generic launches and Semaglutide uptake as key FY2027 catalysts.
Final Verdict: A Painful Quarter, But Recovery in Sight
Dr Reddy’s Q4 FY2026 will go down as one of the most challenging quarters in recent memory for the company — not because of business failure, but because a single high-margin product’s pricing power evaporated overnight. The base business, India segment, and international geographies have all shown resilience.
The company now enters FY2027 with a cleaner slate, free from Lenalidomide dependency, and with a credible pipeline in peptides (Semaglutide), biosimilars (Abatacept), and consumer health. The next few quarters will be critical to watch, especially as new US product approvals come through and management delivers on its margin recovery promise.
Disclaimer
This blog does not provide financial, investment, or trading advice. All content is for educational and informational purposes only. Please consult a certified financial advisor before making any investment decisions. The author will not be responsible for any financial losses incurred
